Entrada Therapeutics (TRDA) Net Income towards Common Stockholders (2020 - 2026)

Entrada Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 128.93% year-over-year to -$39.7 million; the TTM figure through Mar 2026 stood at -$166.2 million (down 772.7% YoY), while the FY2025 annual figure was -$143.8 million, down 319.18% from the prior year.
• Net Income towards Common Stockholders was -$39.7 million for Q1 2026 at Entrada Therapeutics, down from -$39.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $55.0 million in Q2 2024 to a low of -$44.2 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$12.9 million across 5 years, with a median of -$21.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders jumped 452.05% in 2024, then tumbled 3794.25% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$24.6 million in 2022, then surged by 61.59% to -$9.5 million in 2023, then soared by 111.22% to $1.1 million in 2024, then sank by 3794.25% to -$39.2 million in 2025, then slipped by 1.33% to -$39.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$39.7 million (Q1 2026), -$39.2 million (Q4 2025), and -$44.2 million (Q3 2025), per Business Quant data.